Catalytic asymmetric aza-Michael addition of fumaric monoacids with multifunctional thiourea/boronic acids by Michigami, Kenichi et al.
Title Catalytic asymmetric aza-Michael addition of fumaricmonoacids with multifunctional thiourea/boronic acids
Author(s)Michigami, Kenichi; Murakami, Hiroki; Nakamura, Takeru;Hayama, Noboru; Takemoto, Yoshiji




This is the accepted manuscript of the article, which has been
published in final form at
https://doi.org/10.1039/C9OB00045C.; The full-text file will be
made open to the public on 29 January 2020 in accordance with
publisher's 'Terms and Conditions for Self-Archiving'.; This is






Journal Name  
COMMUNICATION 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1  
Please do not adjust margins 
Please do not adjust margins 
Received 00th January 20xx, 
Accepted 00th January 20xx 
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
Catalytic asymmetric aza-Michael addition of fumaric monoacids 
with multifunctional thiourea/boronic acids  
Kenichi Michigami, Hiroki Murakami, Takeru Nakamura, Noboru Hayama, and Yoshiji Takemoto*
The first chemical enantioselective synthesis of N-
hydroxyaspartic acid derivatives using chiral multifunctional 
thiourea/boronic acid organocatalysts was developed. A series 
of fumaric monoacids underwent an intermolecular asymmetric 
aza-Michael addition of O-alkyl hydroxylamines in excellent 
regioselectivity. The addition of another carboxylic acid raised 
the enantiomeric enrichment up to 97% ee. O-Deprotection of 
the aza-Michael adduct provided an aspartate-derived 
hydroxylamine fragment applicable for KAHA (α-keto acid-
hydroxylamine) ligation.  
Chemoselective peptide conjunction by enzymes is a ubiquitous 
process in nature, producing only recyclable phosphates as by-
products.1 Meanwhile, a general chemical approach for the 
amide C–N bond formation is based on stoichiometric activation 
of carboxylic acids by coupling reagents.2 Though this method is 
highly reliable, reagent-derived non-recyclable side products are 
inevitably generated. In addition, protection of nucleophilic 
functional groups is required due to incompatibility with 
condensation reagents. The development of environmentally 
benign alternatives is thus highly demanded.3 Among large 
numbers of strategies reported to circumvent these issues, 
elegant examples have been disclosed in recent years by Bode 
and co-workers. The protocol of simply mixing α-keto acids and 
hydroxylamines in aqueous solvent under mild conditions afford 
amides concomitant with the release of carbon dioxide (CO2) and 
water.4 This clean amide synthesis, KAHA ligation, has manifested 
significant advantages in polypeptide synthesis because the 
connection of peptide segments proceeds without protection of 
side chains and the loss of enantiopurity.4a However, low 
accessibility of both α-keto acids and hydroxylamines underlies a 
major problem that affects the practical convenience. In marked 
contrast to α-amino acid-derived α-keto acids,5 synthetic 
research for hydroxylamine counterparts is still less exploited:6 
only a few simple derivatives including cyclic analogues of 
homoserine, serine, and aspartic acid semialdehyde (Asa) have 
been synthesised and applied to KAHA peptide ligation (Scheme 
1A).4b,6d,7 Since these nucleophiles require long-step routes for 
preparation, a straightforward and enantioselective synthesis of 
such hydroxylamines represents a major challenge for KAHA 
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Scheme 1. Strategy for the Synthesis of α-Amino Acid-Derived 
Hydroxylamines for KAHA Peptide Ligation 
We have recently focused on a direct catalytic asymmetric aza-
Michael addition of BnONH2 to α,β-unsaturated carboxylic acids 
using organocatalysts consisting of arylboronic acid and chiral 
trans-1,2-cyclohexanediamine-based aminothiourea (Scheme 
1B).8-10 Notably, our multifunctional catalysts only promoted 1,4-
addition: The 1,2-adducts, N-benzyloxyamides, which are usually 
formed in organoboron-catalysed dehydrative amidation,11 were 
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not observed. Encouraged by the efficient protocols free from 
“pre-activation” and “protection” of carboxylic acids,12 we 
targeted N-hydroxyaspartic acid derivatives to demonstrate 
synthetic versatility of our catalytic systems. Although 
biocatalytic synthesis of enantiopure N-hydroxy and N-
alkoxyaspartates have been reported,13 chemical methods are 
still under developed, and to the best of our knowledge, no 
example has emerged for catalytic asymmetric variant.14 Herein, 
we report the asymmetric synthesis of N-hydroxyaspartic acid 
derivatives catalysed by multifunctional thiourea/boronic acids, 
which would offer a new, facile access to aspartate-derived 
hydroxylamine fragments suitable for KAHA peptide ligation. 
First, initial investigations focused on catalytic asymmetric aza-
Michael addition using mono-tert-butyl fumarate (1a) and O-
benzylhydroxylamine (2a) as a nucleophile. In line with our 
previous studies, a chiral integrated thiourea/boronic acid 
catalyst A was employed in the presence of 4 Å molecular sieves 
(4 Å MS) at room temperature.8c Though no reaction took place 
in DMF and MeCN (Table 1, entries 1 and 2), the reaction in less 
polar solvents, Et2O and CH2Cl2, furnished the corresponding N-
benzyloxyaspartic acid diester 3aa after treatment with TMSCHN2 
(entries 3 and 4). When the reaction was conducted in toluene, 
both the yield and ee drastically increased (entry 5). CCl4 was 
found to be the optimal solvent, providing 3aa in 80% yield and 
88% ee (entry 6). Next, thiourea moiety of the catalyst was 
deviated. Loss of both yields and ees was observed with electron-
withdrawing thioureas B and C (entries 7 and 8). The ortho-Me 
substituted catalyst D gave slightly higher ee, but the yield 
dropped to 59%. N-Methyl thiourea catalyst E also promoted the 
reaction, albeit in moderate yield and ee (entry 10). Therefore, 
we continued the following experiments with catalyst A. 
Afterwards, a range of carboxylic acid was employed as additives, 
since our previous works suggested three molecules of carboxylic 
acid were involved in catalytic cycle: Two of them bind to the 
catalyst and the other one works as a proton shuttle (vide infra).8c 
No reaction occurred with 1 equivalent of HCO2H, and AcOH or 
tBuCO2H did not exhibit beneficial effects. Meanwhile, both the 
yield and ee improved with PhCO2H, affording 3aa in 88% yield 
and 93% ee (entry 14). In sharp contrast, a highly acidic p-TsOH 
inhibited the reaction completely, probably due to the 
protonation of the nucleophile and/or the catalyst (entry 15). 
Control experiments revealed that both the catalyst and 4 Å MS 
were essential for the reaction (entries 16 and 17). All reactions 
proceeded at β position of the carboxylic acid exclusively, which 
indicates that the carboxylic acid was predominantly activated in 
situ by boronic acid over the alkyl ester moiety.15 







 2a (1.1 equiv)
additive (1 equiv)




entry catalyst additive solvent 3aa (%)a ee (%)b 
1 A - DMF 0 - 
2 A - MeCN 0 - 
3 A - Et2O 22 28 
4 A - CH2Cl2 10 47 
5 A - toluene 60 69 
6 A - CCl4 80 88 
7 B - CCl4 66 80 
8 C - CCl4 72 76 
9 D - CCl4 59 90 
10 E - CCl4 62 80 
11 A HCO2H CCl4 0 - 
12 A MeCO2H CCl4 57 91 
13 A tBuCO2H CCl4 77 87 
14 A PhCO2H CCl4 88 93 
15 A p-TsOH·H2O CCl4 0 - 
16 none - CCl4 0 - 
17c A - CCl4 0 - 
Reaction conditions: 1a (0.10 mmol), 2a (0.11 mmol, 1.1 equiv), 
catalyst (0.010 mmol, 10 mol%), additive (0.10 mmol, 1.0 equiv), 4 Å 
MS (50 mg), solvent (1.0 mL, 0.1 M), rt, 24 h. aIsolated yields are 
shown. bEes were estimated by chiral HPLC analysis. cThe reaction 


















With the optimal conditions in hand, we next explored the 
substrate scope of the aza-Michael addition of fumaric acid 
monoesters with 2a in the presence of catalyst A. (Figure 1). 
Benzyl ester 1b and ethyl ester 1c were converted into the 
corresponding aspartates 3ba and 3ca, respectively in moderate 
yields with high ees. Remarkably, in addition to fumaric acid 
monoesters, phenylalanine-derived fumaric acid monoamides 1d 
and 1e underwent the aza-Michael addition. By employing 
catalyst A with (R,R) configuration, D-Phe-D-Asp derivative 3ea 
was furnished in higher diastereoselectivity than that of L-Phe-D-
Asp derivative 3da. The catalyst was switched to (S,S)-A (ent-A) 
for the reaction of N-fumaryl-L-amino esters 1f and 1g, producing 
Gly-L-Asp and L-Ser-L-Asp derivatives 3fa and 3ga, respectively. 
Even though the stereoselectivity is moderate, these results 
suggest the feasibility of the synthesis of N-hydroxyaspartate-
derived peptides through this protocol.  
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Figure 1. Substrate scope of fumaric monoacids (0.40 mmol). 
Isolated yields are shown. Ees were estimated by chiral HPLC analysis. 
aDr was determined by 1H NMR analysis. bent-A was used as a 
catalyst.  
The efficiency and high stereoselectivity of the aza-Michael 
addition of BnONH2 led us to the examination of various O-
substituted hydroxylamines. To evaluate O-substituent effect of 
nucleophiles 2a-2e on ee, the aza-Michael addition of 1a was 
examined under the optimal conditions (Figure 2). The use of 
electron-rich hydroxylamine 2b resulted in lower yield and 
enantioselectivity, whereas electron-deficient p-CF3 substituted 
nucleophile 2c gave 3ac in 96% ee. Besides, acetal-protected 
nucleophiles such as BOMONH2 (2d) and SEMONH2 (2e) were also 
competent nucleophiles, affording the corresponding adducts 
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Figure 2. Screening of Nucleophiles (0.20–0.40 mmol). Isolated yields 
are shown. Ees were estimated by chiral HPLC analysis. aEe was 
determined after N-benzoylation.  
Based on the experimental results, including perfect 
regioselectivity and mechanistic studies performed previously,8c 
a proposed transition state of the addition of hydroxylamine is 
depicted in Figure 3. Since no reaction occurred in the absence of 
4 Å MS (Table 1, entry 17), removal of water is indispensable for 
this reaction. In a plausible intermediate containing 
diacyloxyboronate, the hydrogen-bond interaction between the 
thiourea NH protons and one of the carboxy group facilitates 
conjugate addition of hydroxylamine. The high enantioselectivity 
would be attributed to an additional interaction between the 
nucleophile NH proton and another carboxy ligand, accelerating 
Re-face attack of hydroxylamine. The nucleophilic addition is 
accompanied with intermolecular proton transfer, which is 





















































Figure 3. Proposed Transition State of Nucleophilic Addition.  
A quick access to various chiral N-alkoxyaspartate derivatives 
prompted us to examine O-deprotection of the Michael adducts 
for the application to KAHA ligation. Various deprotection 
conditions tested revealed that compound 3be, obtained from 1b 
and 2e, was the substrate of choice. First, treatment of 3be with 
TFA and subsequent careful quenching with water gave an OH-
free hydroxylamine 4b in 42% yield.15,16 The following KAHA 
ligation using α-keto acid 5 proceeded smoothly and the 
corresponding amide 6b was obtained without significant loss of 
enantiomeric excess.7a The same reaction with Fmoc-L-leucine-
derived α-keto acid 717 also afforded dipeptide 8b in moderate 
yield without epimerisation. 
 
Scheme 3. O-Deprotection and KAHA Ligation of Asparatate-
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In summary, we have developed a direct aza-Michael 
addition of hydroxylamine derivatives to various fumaric 
monoacids catalysed by multifunctional thiourea/boronic 
acids. The process enables the first catalytic asymmetric 
chemical synthesis of N-hydroxyaspartic acid derivatives 
with perfect regioselectivity and high enantioselectivity. 
Deprotection of the SEMONH2-adduct provides a new 
aspartate-derived hydroxylamine fragment for KAHA 
peptide ligation. Further research into the synthetic 
application is actively ongoing, and the results will be 
reported in due course. 
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(A) Supplemental Data 
(A-1) Optimisation Details: Tables S1-S8 
Several reaction parameters of the enantioselective aza-Michael addition were investigated. In each tables 
are described isolated yields. 
 




 2a (1.1 equiv)
1a


















entry solvent 3aa (%) ee (%) entry solvent 3aa (%) ee (%) 
1 DMF 0 - 7 hexane 35 38 
2 MeCN 0 - 8 CCl4 70 88 
3 EtOAc 0 - 9 C2Cl4 70 81 
4 Et2O 22 28 10 4-F3CC6H4Cl 55 73 
5 CH2Cl2 10 47 11 PhF 15 62 
6 toluene 60 69 12 PhCl 29 7 
 
Table S2. Deviation of Thioureas of Multifunctional Organoboron Catalysts 
catalyst (10 mol%)
BnONH2
















entry catalyst 3aa (%) ee (%) 
1 A 80 88 
2 B 66 80 
3 C 72 76 
4 D 59 90 
5 E 62 80 




















































 2a (1.1 equiv)
1a
additive (1 equiv), MS4A
CCl4

















entry additive 3aa (%) ee (%) 
1 none 80 88 
2 HCO2H 0 - 
3 MeCO2H 57 91 
4 tBuCO2H 77 87 
5 PhCO2H 76 93 
6 TsOH·H2O 0 - 
 
Table S4. Investigation of Nucleophiles 

























rt, rt, 24  h;;
















entry nucleophile 3aa (%) ee (%) 
1 2a 76 93 
2 2b 50 74 
3 2c 64 96 
4 2d 60 87 
5a 2e 70 85 
6 S2a 0 - 
aEe was determined after N-benzoylation. 
 
Figure S1. Unsuccessful Substrates 
Monomethyl fumarate (S1a) and fumaryl monoanilide (S1b) did not undergo the aza-Michael addition, 



































(A-2) Determination of Stereochemistry 
The aza-Michael adduct 3aa was converted into N-Fmoc-aspartic diester S3aa and the stereochemistry 
was determined as R configuration by comparison of HPLC charts and optical rotations with (S)-N-Fmoc-





BnO 1) 10% Pd/C, MeOH    rt, H
2
 (1 atm)
2) FmocCl, iPr2NEt    CH
2Cl2, 0 ºC to rt S3aa































All manipulations were carried out under argon atmosphere unless otherwise noted. Infrared (IR) spectra 
were recorded on a JASCO FT/IR-4100 Fourier transform infrared spectrophotometer. NMR spectra were 
recorded on a JEOL ECP-400 spectrometer and JEOL ECA-500 spectrometer, operating at 400 MHz (1H) 
or 100 MHz (13C) and 500 MHz (1H) or 125 MHz (13C), respectively. Chemical shifts in CDCl3, DMSO-
d6, and CD3OD were reported in the scale relative to CHCl3 (7.26 ppm), DMSO (2.50 ppm), and MeOH 
(3.31 ppm) for 1H NMR, and to CDCl3 (77.0 ppm) for 13C NMR as internal references, respectively. NMR 
data are reported as follows: chemical shifts, multiplicity (s: singlet, d: doublet, t: triplet, q: quartet, quin: 
quintet, m: multiplet, br: broad signal), coupling constant (Hz), and integration. ESI-HRMS spectra were 
measured on a Shimadzu LCMS-IT-TOF fitted with an ESI. Optical rotations were measured on a JASCO 
P-2200 digital polarimeter with a path length of 1 cm; concentrations are quoted in grams per 100 mL. 
[α]𝐷𝐷values are measured in 10
–1 deg cm2/g. Chiral HPLC analyses were carried out using a SHIMADZU 
DGU-20A5. Column chromatography was performed with Cica silica gel 60N (40-100 μm, spherical, 
neutral). Dry solvents were purchased from Wako Pure Chemical Industries, Ltd. and used as received. 
Organocatalysts A-F were prepared according to our developed procedures.1 
S7 
 
(C) Materials and Methods 
(C-1) Preparation of Substrates 
Monoethyl fumarate (1c) was purchased from Tokyo Chemical Industry Co., Ltd. Monomethyl fumarate 
(S1a) was purchased from Sigma-Aldrich Co. LLC. mono-tert-butyl fumarate (1a)2 and (E)-4-oxo-4-
(phenylamino)but-2-enoic acid (S1b)3 were prepared according to the reported procedures. 
 
Mono-tert-butyl fumarate (1a)2: White solids. 
1H NMR (400 MHz, CDCl3) δ: 6.87 (d, J = 15.6 Hz, 1H), 6.76 (d, J = 15.6 Hz, 1H), 
1.52 (s, 9H) ppm. 
 
 
(E)-4-Oxo-4-(phenylamino)but-2-enoic acid (S1b)3: White solids. 
IR (neat) ν�: 1696, 1654 cm-1; 1H NMR (400 MHz, DMSO-d6) δ: 12.99 (br s, 
1H), 10.51 (s, 1H), 7.67 (d, J = 8.0 Hz, 2H), 7.34 (t, J = 7.6 Hz, 2H), 7.14 (d, J 
= 15.2 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 6.65 (d, J = 15.2 Hz, 1H) ppm; 13C 
NMR (100 MHz, DMSO-d6) δ: 166.4, 161.6, 138.6, 137.2, 130.8, 128.9, 124.0, 
119.4 ppm; HRMS (ESI) m/z calcd. for [M-H]-: 190.0510, found: 190.0521. 
 
Monobenzyl fumarate (1b)4: To a solution of benzyl tert-butyl fumarate5 (262.1 mg, 1.0 mmol, 1 equiv) 
in CH2Cl2 (4.0 mL) was added TFA (1.8 mL) and stirred at room temperature for 7 
h. The mixture was concentrated, and the resulting solids were recrystallised from 
CH2Cl2 and hexane to afford 1b as white solids (138.4 mg, 0.67 mmol, 67%).  
IR (neat) ν�: 2940, 1719, 1694 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.39-7.34 (m, 5H), 6.99 (d, J = 16.0 
Hz, 1H), 6.88 (d, J = 16.0 Hz, 1H), 5.25 (s, 2H) ppm. 
 
Ethyl (S,E)-4-((1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobut-2-enoate (S1d):  
A mixture of L-phenylalanine tert-butyl ester hydrochloride6 (1.32 g, 6.0 
mmol, 1.0 equiv), monoethyl fumarate (944.0 mg, 6.6 mmol, 1.1 equiv), 
HOBt (972.0 mg, 7.2 mmol, 1.2 equiv), Et3N (1.82 g, 18.0 mmol, 3.0 
equiv) and EDCI (1.38 g, 7.2 mmol, 1.2 equiv) in DMF (30 mL) was stirred 
at room temperature for 20 h. The solution was diluted with brine (20 mL) and extracted with Et2O (20 mL, 
2 times). The combined organic phase was dried over Na2SO4 followed by filtration and concentration 
under reduced pressure. The residue was then purified by silica-gel column chromatography (eluent: 
hexane/EtOAc, 3:1) to afford S1d as white solids (1.43 g, 4.12 mmol, 67%). 
m.p. 139.3-140.0 ˚C;  [α]D
19 106.9 (c 0.89, CHCl3); IR (neat) ν�: 3312, 1734, 1716, 1637 cm-1; 1H NMR 
(500 MHz, CDCl3) δ: 7.29-7.22 (m, 3H), 7.14 (d, J = 6.0 Hz, 2H), 6.92 (d, J = 15.5 Hz, 1H), 6.80 (d, J = 
15.5 Hz, 1H), 6.45 (d, J = 7.5 Hz, 1H), 4.84 (dt, J = 7.0, 6.0 Hz, 1H), 4.22 (q, J = 7.5 Hz, 2H), 3.14 (d, J = 
6.0 Hz, 2H), 1.42 (s, 9H), 1.30 (t, J = 7.5 Hz, 3H), 13C NMR (125 MHz, CDCl3) δ: 170.2, 165.5, 163.0, 
135.9, 130.9, 129.6, 128.5, 127.2, 82.9, 61.3, 53.9, 37.9, 28.0, 14.2 ppm; HRMS (ESI) m/z calcd. for 
C19H25NO5 [M+Na]+: 370.1625, found: 370.1588. 






of S1d (1.43 g, 4.12 mmol, 1.0 equiv) in THF (20 mL) and water (8.0 mL) was added LiOH (172.8 mg, 
4.12 mmol, 1.0 equiv) and stirred at room temperature for 12 h. The mixture 
was washed with Et2O, and the aqueous phase was acidified with 1 M HCl 
aq. The solution was extracted with EtOAc (20 mL, 2 times) and the 
combined organic layer was washed with brine. After drying over Na2SO4 
followed by filtration, the solvent wasremoved under reduced pressure to afford 1d as white solids (565.3 
mg, 1.77 mmol, 43%). 
m.p. 118.7-119.1˚C;  [α]D
20 105.8 (c 0.68, CHCl3); IR (neat) ν�: 3350, 1726, 1659, 1642cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.29-7.24 (m, 3 H), 7.15-7.14 (m, 2 H), 7.00 (d, J = 15.5 Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 
6.82 (d, J = 15.0 Hz, 1H), 4.89 (dt, J = 8.0, 7.0 Hz, 1H), 3.13 (d, J = 6.0 Hz, 2H), 1.42 (s, 9H) ppm; 13C 
NMR (125 MHz, CDCl3) δ: 170.9, 169.4, 163.1, 137.6, 135.7, 130.3, 129.6, 128.6, 127.3, 83.4, 54.0, 38.1, 
28.0 ppm; HRMS (ESI) m/z calcd. for C17H21NO5 [M+Na]+: 342.1312, found: 342.1295. 
 
Ethyl (R,E)-4-((1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobut-2-enoate (S1e):  
A mixture of D-phenylalanine t-butyl ester hydrochloride6 (1.32 g, 6.0 
mmol, 1.0 equiv), monoethyl fumarate (944.0 mg, 6.6 mmol, 1.1 equiv), 
HOBt (972.0 mg, 7.2 mmol, 1.2 equiv), Et3N (1.82 g, 18.0 mmol, 3.0 
equiv) and EDCI (1.38 g, 7.2 mmol, 1.2 equiv) in DMF (30 mL) was stirred 
at room temperature for 20 h. The solution was diluted with brine (20 mL) and extracted with Et2O (20 mL, 
2 times). The combined organic phase was dried over Na2SO4 followed by filtration and concentration 
under reduced pressure. The residue was then purified by silica-gel column chromatography (eluent: 
hexane/EtOAc, 3:1) to afford S1d as white solids (1.46 g, 4.23 mmol, 70%). 
m.p. 135.5-137.8 ˚C;  [α]D
18 -91.3 (c 0.94, CHCl3); IR (neat) ν�: 3310, 1734, 1716, 1636 cm-1; 1H NMR 
(500 MHz, CDCl3) δ: 7.27-7.22 (m, 3H), 7.15-7.13 (m, 2H), 6.94 (d, J = 15.5 Hz, 1H), 6.81 (d, J = 14.5 
Hz, 1H), 6.54 (d, J = 7.5 Hz, 1H), 4.85 (dt, J = 7.5, 6.0 Hz, 1H), 4.21 (q, J = 7.0 Hz, 2H), 3.14 (d, J = 6.0 
Hz, 2H), 1.41 (s, 9H), 1.29 (t, J = 7.5 Hz, 3H), 13C NMR (125 MHz, CDCl3) δ: 170.3, 165.5, 163.0, 135.95, 
135.91, 130.9, 129.5, 128.5, 127.1, 82.8, 61.3, 53.9, 37.9, 28.0, 14.2 ppm; HRMS (ESI) m/z calcd. for 
C19H25NO5 [M+Na]+: 370.1625, found: 370.1576. 
 
(R,E)-4-((1-(tert-Butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobut-2-enoic acid (1e): To a solution 
of S1e (1.46 g, 4.23 mmol, 1.0 equiv) in THF (20 mL) and water (8.0 mL) 
was added LiOH. (177.4 mg, 4.23 mmol, 1.0 equiv) and stirred at room 
temperature for 12 h. The mixture was washed with Et2O, and the aqueous 
phase was acidified with 1 M HCl aq. The solution was extracted with 
EtOAc (20 mL, 2 times) and the combined organic layer was washed with brine. After drying over Na2SO4 
followed by filtration, the solvent was removed under reduced pressure to afford 1e as white solids (855.0 
mg, 2.67 mmol, 65 %). 
m.p. 118.6-119.2˚C;  [α]D
21 -95.0 (c 0.48, CHCl3); IR (neat) ν�: 3351, 1726, 1660, 1642cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.29-7.24 (m, 3 H), 7.14 (d, J = 7.0 Hz, 2 H), 6.99 (d, J = 15.5 Hz, 1H), 6.81 (d, J = 15.0 
Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 4.88 (dt, J = 8.0, 6.0 Hz, 1H), 3.14 (d, J = 6.5 Hz, 2H), 1.42 (s, 9H) ppm; 
13C NMR (125 MHz, CDCl3) δ: 170.9, 169.4, 163.0, 137.6, 130.2, 129.6, 128.6, 127.3, 83.4, 54.0, 38.0, 
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28.0 ppm; HRMS (ESI) m/z calcd. for C17H21NO5 [M+Na]+: 342.1312, found: 342.1291. 
 
Ethyl (E)-4-((tert-butoxycarbonylmethyl)amino)-4-oxobut-2-enoate (S1f): A mixture of glycine tert-
butyl ester hydrochloride (835.0 mg, 4.98 mmol, 1.0 equiv), monoethyl 
fumarate (788.4 mg, 5.47 mmol, 1.1 equiv), HOBt (1.01 g, 7.47 mmol, 1.5 
equiv), and EDCI (1.43 g, 7.47 mmol, 1.5 equiv) in DMF (13.5 mL) was 
stirred at room temperature for 20 h. The solution was diluted with brine (30 
mL) and extracted with Et2O (50 mL, 3 times). The combined organic phase was dried over Na2SO4 
followed by filtration and concentration under reduced pressure. The residue was then purified by silica-
gel column chromatography (eluent: hexane/EtOAc, 1:1) to afford S1f as yellow oil (716.7 mg, 2.78 mmol, 
56%). 
IR (neat) ν�: 3301, 2980, 1724, 1668 cm-1; 1H NMR (500 MHz, CDCl3) δ: 6.94 (d, J = 15.0 Hz, 1H), 6.82 
(d, J =15.0 Hz, 1H), 4.24 (q, J = 7.0 Hz, 2H), 4.03 (d, J = 4.5 Hz, 2H), 1.47 (s, 9H), 1.31 (t, J = 6.5 Hz, 3H) 
ppm; 13C NMR (125 MHz, CDCl3) δ: 168.6, 165.5, 163.6, 135.5, 131.1, 82.9, 61.3, 42.4, 28.1, 14.2 ppm; 
HRMS (ESI) m/z calcd. for [M+Na]+: 280.1155, found: 280.1157. 
 
(E)-4-((tert-Butoxycarbonylmethyl)amino)-4-oxobut-2-enoic acid (1f): A solution of S1f (716.0 mg, 
2.78 mmol, 1 equiv) in THF (14 mL) was treated with 1 M LiOH aq. (2.78 
mL, 2.78 mmol, 1.0 equiv) and stirred at ambient temperature for 4 h. The 
mixture was acidified with 1 M HCl aq. and extracted with CHCl3 (30 mL, 3 
times). After drying over Na2SO4 followed by filtration, the solvent was 
removed under reduce pressure to afford 1f as white solids (366.7 mg, 1.60 mmol, 60%). 
m.p. 229.4 ˚C (decomp.); IR (neat) ν�: 3339, 2868, 1732, 1689, 1658, 1637 cm-1; 1H NMR (500 MHz, 
CDCl3) δ: 7.02 (d, J = 15.5 Hz, 1H), 6.84 (d, J = 15.5 Hz, 1H), 6.54 (br s, 1H), 4.06 (d, J = 4.5 Hz, 2H), 
1.48 (s, 9H) ppm; 13C NMR (125 MHz, CD3OD) δ: 168.6, 166.9, 165.3, 135.6, 130.5, 81.7, 41.6, 26.9 ppm; 
HRMS (ESI) m/z calcd. for [M-H]-: 228.0877, found: 228.0868. 
 
Ethyl (S,E)-4-((1,3-bis(tert-butoxy)-1-oxopropan-2yl)amino)-4-oxobut-2-enoate (S1g): A mixture of 
O-tert-butyl-L-serine tert-butyl ester hydrochloride (2.53 g, 10.0 mmol, 1.0 
equiv), monoethyl fumarate (1.72 g, 12.0 mmol, 1.2 equiv), HOBt (1.62 g, 
12.0 mmol, 1.2 equiv), and EDCI (2.87 g, 15.0 mmol, 1.5 equiv) in DMF (27 
mL) was stirred at room temperature for 12 h. The solution was diluted with 
brine (50 mL) and extracted with Et2O (50 mL, 3 times). The combined organic phase was dried over 
Na2SO4 followed by filtration and concentration under reduced pressure. The residue was then purified by 
silica-gel column chromatography (eluent: hexane/EtOAc, 1:1) to afford S1g as white solids (3.06 g, 8.91 
mmol, 89%). 
m.p. 79.4- 80.5 ˚C; [α]D
25 43.2 (c 0.45, CHCl3); IR (neat) ν�: 3309, 2981, 1741, 1715, 1656 cm-1; 1H NMR 
(125 MHz, CDCl3) δ: 6.99 (d, J = 15.5 Hz, 1H), 6.96 (d, J = 8.5 Hz, 1H), 4.60 (dt, J = 8.0, 3.0 Hz, 1H), 
4.13 (q, J = 7.0 Hz, 2H), 3.69 (dd, J = 8.0, 3.0 Hz, 1H), 3.46 (dd, J = 8.0, 3.0 Hz, 1H), 1.35 (s, 9H), 1.18 (t, 
J = 7.0 Hz, 3H), 1.01 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 169.0, 165.5, 163.2, 136.3, 130.5, 81.9, 





















(S,E)-4-((1,3-Bis(tert-butoxy)-1-oxopropan-2-yl)amino)-4-oxobut-2-enoic acid (1g): A solution of S1g 
(1.03 g, 3.0 mmol, 1.0 equiv) in THF (15 mL) was treated with 1 M LiOH aq. 
(3.0 mL, 3.0 mmol, 1.0 equiv) and stirred at ambient temperature for 4 h. The 
mixture was acidified with 1 M HCl aq. and extracted with CHCl3 (20 mL, 3 
times). After drying over Na2SO4 followed by filtration, the solvent was 
removed to afford 1g as white solids (836.9 mg, 2.65 mmol, 88%). 
m.p. 165.5-167.9˚C;  [α]D
23 25.6 (c 0.42, CHCl3); IR (neat) ν�: 3331, 3074, 1720, 1706, 1631 cm-1; 1H NMR 
(500 MHz, CDCl3) δ: 7.19 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 15.5 Hz, 1H), 6.88 (d, J = 15.5 Hz, 1H), 4.73 
(dt, J = 9.0, 3.0 Hz, 1H), 3.80 (dd, J = 9.0, 3.0 Hz, 1H), 3.56 (dd, J = 9.0, 3.0 Hz, 1H), 1.45 (s, 9H), 1.12 (s, 
9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 169.7, 168.8, 137.3, 130.5, 82.8, 73.5, 62.2, 53.6, 28.0, 27.3 
ppm; HRMS (ESI) m/z calcd. for C15H25NO6[M+Na]+: 338.1574, found: 338.1554. 
 
 
(C-2) Preparation of Nucleophiles 
O-benzylhydroxylamine (2a) was prepared by neutralization of BnONH2·HCl by 4 M NaOH aq. After 
extraction with CHCl3, general work up and dried under vacuum to afford 2a. O-Benzoylhydroxylamine 
(S2a) was prepared according to the reported procedure.8 
 
O-(4-Methoxybenzyl)hydroxylamine (2b): A mixture of N-hydroxyphthalimide (1.80 g, 11.0 mmol, 1.1 
equiv), 4-methoxybenzyl chloride (1.86 g, 10.0 mmol, 1.0 equiv), and Et3N (1.22 
g, 12.1 mmol, 1.1 equiv) in CH2Cl2 (25 mL) was stirred at room temperature for 
4 h. The suspension was washed with brine (20 mL, 3 times) and the combined 
organic phase was dried over Na2SO4. After the solvent was removed under reduced pressure, the residue 
was dissolved in CHCl3/MeOH = 3:1 (50 mL). To the solution was added to N2H4·H2O (750.9 mg, 15.0 
mmol, 1.5 equiv) and stirred at room temperature for 2 h. The mixture was filtered through a pad of Celite® 
and the filtrate was concentrated under reduced pressure. The residue was purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 1:1) to afford 2b as colorless oil (1.10 g, 6.2 mmol, 62%). 
IR (neat) ν�: 2977, 2917 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.29 (d, J = 9.0 Hz, 2H), 6.89 (d, J = 9.0 Hz, 
2H), 5.33 (br s, 2H), 4.61 (s, 2H), 3.80 (s, 3H) ppm; 13C NMR (125 MHz, CDCl3) δ: 159.5, 130.1, 129.4, 
113.9,113.7, 77.7, 53.3 ppm; HRMS (ESI) m/z calcd. for C8H9NO, [M]+: 176.0682, found: 176.0556. 
 
O-(4-Trifluoromethylbenzyl)hydroxylamine (2c): 2c was prepared through the procedure analogous to 
that of 2b. Alkylation was performed using N-hydroxyphthalimide (1.35 g, 7.0 
mmol, 1.4 equiv), 4-(trifluoromethyl)benzyl chloride (815.0 mg, 5.0 mmol, 1.0 
equiv), and Et3N (708.3 mg, 7.0 mmol, 1.4 equiv) in CH2Cl2 (20 mL). Deprotection 
of phthalimide was conducted with N2H4·H2O (525.6 mg, 10.5 mmol, 1.5 equiv) in CH3Cl/MeOH = 3:1 
(15 mL), which afforded 2c as colorless oil (810.0 mg, 4.2 mmol, 84%). 
IR (neat) ν�: 2940, 1323 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.63 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 

















125.4 (q, J = 3.9 Hz), 76.9 ppm; HRMS (ESI) m/z calcd. for C8H8FNO, [M+H]+: 192.0631, found: 192.0579. 
 
O-(Benzyloxymethyl)hydroxylamine (2d): 2d was prepared through the procedure analogous to that of 
2b. Alkylation was performed using N-hydroxyphthalimide (322.6 mg. 2.0 mmol, 
1.0 equiv), chloromethyl benzyl ether (439.1 mg, 2.8 mmol, 1.4 equiv), and Et3N 
(286.0 mg, 2.8 mmol, 1.4 equiv) in CH2Cl2 (4.5 mL). Deprotection of phthalimide 
was conducted with N2H4·H2O (150.2 mg, 3.0 mmol, 1.5 equiv) in CH3Cl/MeOH = 3:1 (5 mL), which 
afforded 2d as colorless oil (213.4 mg, 1.4 mmol, 70%). 
IR (neat) ν�: 2871 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.38-7.34 (m, 4H), 7.32-7.29 (m, 1H), 5.51 (br s, 
2H), 4.85 (s, 2H), 4.67 (s, 2H) ppm; 13C NMR (125 MHz, CDCl3) δ: 137.1, 128.4, 127.7, 98.5, 69.9 ppm; 
HRMS (ESI) m/z calcd. for C8H12NO2, [M]+: 154.0865, found: 154.0805. 
 
O-((2-Trimethylsilylethoxy)methyl)hydroxylamine (2e): 2e was prepared through the procedure 
analogous to that of 2b. Alkylation was performed using N-hydroxyphthalimide 
(815.5 mg. 5.0 mmol, 1.0 equiv), chloromethyl 2-(trimethylsilyl)ethyl ether 
(1.16 g, 7.0 mmol, 1.4 equiv), and Et3N (708.3 mg, 7.0 mmol, 1.4 equiv) in 
CH2Cl2 (11.4 mL). Deprotection of phthalimide was conducted with N2H4·H2O (375.5 mg, 7.5 mmol, 1.5 
equiv) in CH3Cl/MeOH = 3:1 (10 mL), which afforded 2e as colorless oil (550.5 mg, 3.1 mmol, 62%). 
IR (neat) ν�: 2953 cm-1; 1H NMR (500 MHz, CDCl3) δ: 5.47 (br s, 2H), 4.73 (s, 2H), 3.64 (t, J = 8.0 Hz, 
2H), 0.96 (t, J = 8.0 Hz, 2H), 0.01 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 98.8, 65.7, 18.3 ppm; 
HRMS (ESI) m/z calcd. for C6H17NO2Si, [M+H]+: 164.1107, found: 164.1018. 
 
O-Benzoylhydroxylamine (S2a)7: Colorless oil. 
1H NMR (400 MHz, CDCl3) δ: 8.00 (d, J = 2.0 Hz, 2H), 7.58 (t, J = 7.6 Hz, 1H), 7.45 
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Prior to the reaction, 4 Å MS was dried by heat-gun (>300 ºC, 15 min) under vacuum (ca. 2 Torr). To an 
oven-dried 10 mL screw tube were placed an organocatalyst (10 mol%), substrate 1 (1.0 equiv), and benzoic 
acid (1.0 equiv), which were suspended in CCl4 (0.2 M) and sealed with a Teflon-coated screw cap. After 
stirring at room temperature for 10 min, pre-heated 4 Å MS (500 mg/mmol) was added and the tube was 
capped and further stirred for 5 min. Hydroxylamine 2 (1.1 equiv) was then added and the system was 
closed again followed by stirring at ambient temperature for the indicated time. After the reaction progress 
was monitored by 1H NMR analysis (a small amount of the mixture was transferred into an NMR tube). 
The reaction mixture was diluted in toluene/MeOH (3:1, 1 mL) and treated with TMSCHN2 (10% in hexane, 
1 mL) and stirred for 30 min. The excess TMSCHN2 was quenched with AcOH, then the mixture was 
filtered through Celite® and the cake was washed with MeOH. After the solvent was removed under reduced 
pressure, the residue was purified by silica-gel column chromatography (eluent: hexane/EtOAc, 1:1) to 
afford the product 3. The ee of 3 was estimated by chiral HPLC analysis. 
 
1-tert-Butyl 4-methyl N-benzyloxy-D-aspartate (3aa): The reaction was carried out using 1a (34.4 mg, 
200 µmol, 1.0 equiv) and 2a (27.0 mg, 220 µmol, 1.1 equiv) in the presence of 
catalyst A (7.9 mg, 20 μmol, 10 mol%), benzoic acid (24.4 mg, 200 μmol, 1.0 equiv) 
and 4 Å MS (100.0 mg) for 24 h. The crude product was purified by silica-gel 
column chromatography (eluent: hexane/EtOAc, 3:1) afforded 3aa as colorless oil 
(40.5 mg, 164 μmol, 80%, 93% ee). 
 [α]D
24 +5.4 (c 1.00, CHCl3); IR (neat) ν�: 3275, 1731 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.31 (m, 5H), 
6.18 (br s, 1H), 4.69 (s, 2H), 3.92 (br s, 1H), 3.68 (s, 3H), 2.76 (dd, J = 16.0, 6.4 Hz, 1H), 2.63 (dd, J = 
16.0, 6.4 Hz, 1H), 1.47 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 171.3, 170.6, 137.5, 128.3, 128.2 
127.7, 76.3, 64.2, 60.1, 51.8, 34.3, 27.9 ppm; HRMS (ESI) m/z calcd. for C16H23NO5, [M+Na]+: 332.1468, 
found: 332.1470. The enantiomeric excess was estimated by chiral HPLC analysis (DAICEL CHIRALPAK 
IB, eluent: hexane/2-propanol = 99/1, flow rate: 1.0 mL/min. detector: UV at 220 nm), tR = 12.0 min (minor), 
10.5 min (major). 
 
1-Benzyl 4-methyl N-benzyloxy-D-aspartate (3ba): The reaction was carried out using 1b (82.4 mg, 400 
μmol, 1.0 equiv) and 2a (54.2 mg, 440 µmol, 1.1 equiv) in the presence of catalyst 
A (15.9 mg, 40 μmol, 10 mol%), benzoic acid (48.8 mg, 400 μmol, 1.0 equiv) and 4 
Å MS (200.0 mg) for 24 h. The crude product was purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 2:1) afforded 3ba as colorless oil (69.6 mg, 
201 μmol, 50%, 91% ee). 
 [α]D
26 +4.2 (c 0.94, CHCl3); IR (neat) ν�: 1738 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.34 (m, 10H), 6.26 













Hz, 1H), 4.09 (t, J = 7.0 Hz, 1H), 3.64 (s, 3H), 2.85 (dd, J = 16.0, 6.0 Hz, 1H), 2.70 (dd, J =16.0, 6.0 Hz, 
1H) ppm; 13C NMR (125 MHz, CDCl3) δ: 171.5, 171.2, 137.4, 135.4, 128.68, 128.60, 128.4, 128.3, 128.0, 
76.6, 67.2, 60.2, 52.0, 34.2 ppm; HRMS (ESI) m/z calcd. for C19H21NO5, [M+Na]+: 366.1312, found: 
366.1290. The enantiomeric excess was estimated by chiral HPLC analysis (DAICEL CHIRALPAK IB, 
eluent: hexane/2-propanol = 98/2, flow rate: 1.0 mL/min. detector: UV at 254 nm), tR = 16.1 min (major), 
17.4 min (minor). 
 
1-Ethyl 4-methyl N-benzyloxy-D-aspartate (3ca): The reaction was carried out using 1c (57.6 mg, 400 
µmol, 1.0 equiv) and 2a (54.2 mg, 440 µmol, 1.1 equiv) in the presence of catalyst 
A (15.9 mg, 40 μmol, 10 mol%), benzoic acid (48.8 mg, 400 μmol, 1.0 equiv) and 4 
Å MS (200.0 mg) for 24 h. The crude product was purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 2:1) afforded 3ca as colorless oil (55.2 mg, 
197.6 μmol, 49%, 94% ee). 
 [α]D
26 6.1 (c 1.04, CHCl3); IR (neat) ν�: 3265, 1732 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.31 (m, 5H), 
6.22 (br s, 1H), 4.69 (s, 2H), 4.23 (q, J = 6.8 Hz, 2H), 4.01 (t, J = 6.4 Hz, 1H), 3.68 (s, 3H), 2.81 (dd, J = 
16.4, 6.4 Hz, 1H), 1.28 (t, J = 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3) δ: 171.5, 171.2, 137.4, 128.4, 
128.3, 127.8, 76.5, 61.4, 60.0, 51.9, 34.1, 14.0 ppm; HRMS (ESI) m/z calcd. for C14H19NO5, [M+Na]+: 
304.1155, found: 304.1140. The enantiomeric excess was estimated by chiral HPLC analysis (DAICEL 
CHIRALPAK @, eluent: hexane/2-propanol = 99/1, flow rate: 1.0 mL/min. detector: UV at 254 nm), tR = 
16.9 min (major), 20.1 min (minor). 
 
Methyl (R)-3-((benzyloxy)amino)-4-(((S)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-4-
oxobutanoate (3da): The reaction was carried out using 1d (133.2 mg, 
400 µmol, 1.0 equiv) and 2a (54.2 mg, 440 µmol, 1.1 equiv) in the 
presence of catalyst A (15.9 mg, 40 μmol, 10 mol%), benzoic acid (48.8 
mg, 400 μmol, 1.0 equiv) and and 4 Å MS (200.0 mg) for 24 h. The crude 
product was purified by silica-gel column chromatography (eluent: hexane/EtOAc, 2:1) afforded 3da as 
colorless oil (120.0 mg, 263 μmol, 66%, 67:33 dr). 
For major diastereomer: [α]D
21 39.8 (c 0.51, CHCl3); IR (neat) ν�: 3381, 1730, 1675 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.34-7.14 (m, 10H), 6.19 (d, J = 5.5 Hz, 1H), 4.73 (dt, J = 7.5, 6.0 Hz, 1H), 4.68 (d, J = 
12.0 Hz, 1H), 4.61 (d, J = 12.0 Hz, 1H), 3.81 (m, 1H), 3.66 (s, 3H), 3.11 (dd, J = 15.0, 6.0 Hz, 1H), 3.07 
(dd, J = 15.0, 6.0 Hz, 1H), 2.87 (dd, J = 17.5, 9.0 Hz, 1H), 2.77 (dd, J = 17.0, 9.0 Hz, 1H), 1.40 (s, 9H) 
ppm; 13C NMR (125 MHz, CDCl3) δ: 172.5, 170.4, 170.2, 137.2, 136.3, 129.6, 128.57, 128.52, 128.4, 128.1, 
127.0, 82.4, 76.3, 60.5, 53.6, 52.0, 38.2, 32.2, 28.0 ppm; HRMS (ESI) m/z calcd. for C25H32N2O6, [M+H]+: 
457.2333, found: 457.2353. 
For minor diastereomer:  [α]D21 19.7 (c 0.60, CHCl3); IR (neat) ν�: 3388, 1732, 1674 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.33-7.17 (m, 10H), 6.18 (d, J = 6.0 Hz, 1H), 4.73 (dt, J = 7.5, 6.0 Hz, 1H), 4.62 (d, J = 
11.5 Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H),3.82 (ddd, J = 8.0, 7.0, 4.5 Hz, 1H), 3.65 (s, 3H), 3.11 (dd, J = 14.0, 
6.5 Hz, 1H), 3.08 (dd, J = 14.0, 6.0 Hz, 1H), 2.83 (dd, J = 12.0, 4.5 Hz, 1H), 2.71 (dd, J = 12.0, 8.0 Hz, 
1H), 1.44 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 172.3, 170.47, 170.42, 137.1, 136.2, 129.7, 128.4, 








[M+H]+: 457.2333, found: 457.2354. 
 
Methyl (R)-3-((benzyloxy)amino)-4-(((R)-1-(tert-butoxy)-1-oxo-3-phenylpropan-2-yl)amino)-4-
oxobutanoate (3ea): The reaction was carried out using 1e (133.2 mg, 
400 µmol, 1.0 equiv) and 2a (54.2 mg, 440 µmol, 1.1 equiv) in the 
presence of catalyst A (15.9 mg, 40 μmol, 10 mol%), benzoic acid (48.8 
mg, 400 μmol, 1.0 equiv) and 4 Å MS (200.0 mg) for 24 h. The crude 
product was purified by silica-gel column chromatography (eluent: hexane/EtOAc, 2:1) afforded 3ea as 
colorless oil (128.2 mg, 280 μmol, 70%, 75:25 dr). 
For major diastereomer:  [α]D21 -15.0 (c 0.66, CHCl3); IR (neat) ν�: 3381, 1731, 1674 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.34-7.16 (m, 10H), 6.19 (br s, 1H), 4.73 (dt, J = 7.5, 6.0 Hz, 1H), 4.61 (d, J = 11.5 Hz, 
1H), 4.59 (d, J = 11.5 Hz, 1H), 3.82 (m, 1H), 3.66 (s, 3H), 3.11 (dd, J = 14.0, 6.5 Hz, 1H), 3.08 (dd, J = 
14.0, 6.5 Hz, 1H), 2.83 (dd, J = 12.0, 4.5 Hz, 1H), 2.71 (dd, J = 17.0, 8.0 Hz, 1H), 1.41 (s, 9H) ppm; 13C 
NMR (125 MHz, CDCl3) δ: 172.3, 170.47, 170.42, 137.1, 136.2, 129.7, 128.5, 128.4, 128.1, 127.0, 82.4, 
76.2, 60.6, 53.6, 52.0, 38.1, 32.5, 28.0 ppm; HRMS (ESI) m/z calcd. for C25H32N2O6, [M+H]+: 457.2333, 
found: 457.2328. 
For minor diastereomer:   [α]D22 -43.9 (c 0.57, CHCl3); IR (neat) ν�: 3383, 1729, 1674 cm-1; 1H NMR 
(500 MHz, CDCl3) δ: 7.32-7.14 (m, 10H), 6.19 (d, J = 6.0 Hz, 1H), 4.74 (dt, J = 7.5, 6.5 Hz, 1H), 4.65 (d, 
J = 11.5 Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H), 3.81 (m, 1H), 3.66 (s, 3H), 3.12 (dd, J = 14.0, 6.0 Hz, 1H), 
3.07 (dd, J = 14.0, 6.0 Hz, 1H), 2.87 (dd, J = 17.0, 5.0 Hz, 1H), 2.77 (dd, J = 17.5, 8.0 Hz, 1H), 1.40 (s, 
9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 172.5, 170.4, 170.2, 137.1, 136.3, 129.5, 128.5, 128.49, 128.46, 
128.0, 127.0, 82.3, 76.2, 60.4, 53.6, 51.9, 38.1, 32.2, 28.0 ppm; HRMS (ESI) m/z calcd. for C25H32N2O6, 
[M+H]+: 457.2333, found: 457.2355. 
 
Methyl (S)-3-((benzyloxy)amino)-4-((tert-
butoxycarbonylmethyl)amino)-4-oxobutanoate (3fa): The reaction was 
carried out using 1f (91.6 mg, 400 µmol, 1.0 equiv) and 2a (54.2 mg, 440 
µmol, 1.1 equiv) in the presence of catalyst ent-A (15.9 mg, 40 μmol, 10 
mol%), benzoic acid (48.8 mg, 400 μmol, 1.0 equiv) and 4 Å MS (200.0 mg) for 24 h. The crude product 
was purified by silica-gel column chromatography (eluent: hexane/EtOAc, 2:1) afforded 3fa as colorless 
oil (241.4 mg, 266 μmol, 66%, 63% ee). 
 [α]D
24 4.6 (c 1.46, CHCl3); IR (neat) ν�: 1733, 1669 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.34-7.28 (m, 4H), 
7.19 (m, 1H), 6.46 (br s, 1H), 4.73 (s, 2H), 4.03 (d, J = 5.5 Hz, 1H), 3.88 (dd, J = 5.0, 2.0 Hz, 1H), 3.85 
(dd, J = 5.0, 2.0 Hz, 1H), 3.66 (s, 3H), 2.89 (dd, J = 17.0, 8.0 Hz), 2.78 (dd, J = 17.0, 8.0 Hz), 1.46 (s, 9H) 
ppm; 13C NMR (125 MHz, CDCl3) δ: 172.5, 170.8, 168.7, 130.6, 128.7, 128.5, 128.1, 82.3, 76.2, 60.4, 52.0, 
42.0, 32.3, 28.1 ppm; HRMS (ESI) m/z calcd. for C18H26N2O6, [M+H]+: 367.1864, found: 367.1789. The 
enantiomeric excess was estimated by chiral HPLC analysis (DAICEL CHIRALPAK IB, eluent: hexane/2-












oxobutanoate (3ga): The reaction was carried out using 1g (126 mg, 400 
µmol, 1.0 equiv) and 2a (54.2 mg, 440 µmol, 1.1 equiv) in the presence of 
catalyst ent-A (15.9 mg, 40 μmol, 10 mol%), benzoic acid (48.8 mg, 400 
μmol, 1.0 equiv) and 4 Å MS (200.0 mg) for 24 h. The crude product was 
purified by silica-gel column chromatography (eluent: hexane/EtOAc, 2:1) afforded 3da as colorless oil 
(366.6 mg, 322 μmol, 81%, 73:27 dr). 
For major diastereomer:  [α]D21 33.2 (c 1.02, CHCl3); IR (neat) ν�: 3403, 1735, 1679 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.66 (d, J = 8.0 Hz, 1H), 7.37-7.31 (m, 5H), 6.26 (d, J = 10.0 Hz, 1H), 4.80 (dd, J = 15.0, 
11.5 Hz, 2H), 4.60 (dt, J = 9.0, 2.5 Hz, 1H), 3.90 (dt, J = 7.5, 4.5 Hz, 1H), 3.81 (dd, J = 17.0, 4.5 Hz, 1H), 
3.67 (s, 3H), 3.54 (dd, J = 8.5, 3.0 Hz, 1H), 2.91 (dd, J = 17.0, 4.5 Hz, 1H), 2.76 (dd, J = 17.0, 9.0 Hz, 1H), 
1.47 (s, 9H), 1.13 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 172.4, 170.5, 169.2, 137.3, 128.6, 128.5, 
128.0, 81.8, 76.4, 73.1, 60.7, 53.2, 52.0, 32.6, 28.1, 27.4 ppm; HRMS (ESI) m/z calcd. for C25H32N2O6, 
[M+H]+: 453.2595, found: 453.2570. 
For minor diastereomer: [α]D
21 1.0 (c 0.96, CHCl3); IR (neat) ν�: 3405, 1737, 1679 cm-1; 1H NMR (500 
MHz, CDCl3) δ: 7.61 (d, J = 8.5 Hz, 1H), 7.34-7.26 (m, 5H), 6.26 (d, J = 6.5 Hz, 1H), 4.78 (dd, J = 17.0, 
11.0 Hz, 2H), 4.61 (dt, J = 8.5, 2.5 Hz, 1H), 3.91 (ddd, J = 9.0, 6.5, 3.0 Hz, 1H), 3.81 (dd, J = 9.0, 3.0 Hz, 
1H), 3.67 (s, 3H), 3.54 (dd, J = 9.0, 3.0 Hz, 1H), 2.93 (dd, J = 17.5, 5.0 Hz, 1H), 2.80 (dd, J = 17.5, 9.0 Hz, 
1H), 1.47 (s, 9H), 1.12 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 172.4, 170.5, 169.3, 137.3, 128.58, 
128.51, 128.0, 81.9, 76.4, 73.1, 62.2, 60.5, 53.2, 51.9, 32.3, 28.1, 27.4 ppm; HRMS (ESI) m/z calcd. for 
C25H32N2O6, [M+H]+: 453.2595, found: 453.2524.  
 
1-tert-Butyl 4-methyl N-(4-methoxybenzyl)oxy-D-aspartate (3ab): The reaction was carried out using 
1a (68.8 mg, 400 µmol, 1.0 equiv) and 2b (67.4 mg, 440 µmol, 1.1 equiv) 
in the presence of catalyst A (15.9 mg, 40 μmol, 10 mol%), benzoic acid 
(48.8 mg, 400 μmol, 1.0 equiv) and 4 Å MS (200.0 mg) for 24 h. The 
crude product was purified by silica-gel column chromatography (eluent: 
hexane/EtOAc, 2:1) afforded 3ab as colorless oil (101.8 mg, 300 μmol, 
75%, 89% ee). 
 [α]D
23 8.2 (c 0.68, CHCl3); IR (neat) ν�: 1732 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.26 (t, J = 7.0 Hz, 2H), 
6.86 (d, J = 7.0 Hz, 2H), 6.12 (br s, 1H), 4.61 (s, 2H), 3.80 (s, 3H), 3.68 (s, 3H), 2.75 (dd, J = 16.0, 7.5 Hz, 
1H), 2.62 (dd, J = 16.0, 7.5 Hz, 1H), 1.46 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 171.4, 170.7, 159.4, 
130.1, 129.7, 113.7, 82.1, 76.1, 60.7, 55.3, 51.9, 34.4, 28.0 ppm; HRMS (ESI) m/z calcd. for C17H25NO6, 
[M+H]+: 340.1755, found: 340.1744. The enantiomeric excess was estimated by chiral HPLC analysis 
(DAICEL CHIRALPAK IB, eluent: hexane/2-propanol = 98/2, flow rate: 1.0 mL/min. detector: UV at 254 


















1-tert-Butyl 4-methyl N-(4-trifluoromethyl)benzyloxy-D-aspartate (3ac): The reaction was carried out 
using 1a (34.4 mg, 200 µmol, 1.0 equiv) and 2c (42.0 mg, 220 μmol, 1.1 
equiv) in the presence of catalyst A (7.9 mg, 20 μmol, 10 mol%) and 
benzoic acid (48.8 mg, 400 μmol, 1.0 equiv) and 4 Å MS (200.0 mg) for 
24 h. The crude product was purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 3:1) afforded 3ac as colorless oil 
(48.2 mg, 128 μmol, 64%, 96% ee). 
 [α]D
25 6.6 (c 1.90, CHCl3); IR (neat) ν�: 1732, 1324 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.60 (d, J = 8.0 
Hz, 1H), 7.44 (d, J = 8.0 Hz, 1H), 6.25 (d, J = 6.0 Hz, 1H), 4.75 (s, 2H), 3.93 (dt, J = 6.0 Hz, 1H), 3.67 (s, 
3H), 2.75 (dd, J = 16.0, 6.5 Hz, 1H), 2.61 (dd, J = 16.0, 6.5 Hz, 1H), 1.48 (s, 9H) ppm; 13C NMR (125 
MHz, CDCl3) δ: 171.1, 170.5, 141.7, 129.9 (q, J = 32.6 Hz), 128.2, 125.2 (q, J = 3.7 Hz), 124.1 (q, J = 270 
Hz), 82.2, 75.4, 60.7, 51.8, 51.7, 34.2, 27.9 ppm; HRMS (ESI) m/z calcd. for C17H22NO5F3, [M+Na]+: 
400.1342, found: 400.1333. The enantiomeric excess was estimated by chiral HPLC analysis (DAICEL 
CHIRALPAK IB, eluent: hexane/2-propanol = 99/1, flow rate: 1.0 mL/min. detector: UV at 254 nm), tR = 
15.8 min (minor), 20.2 min (major). 
 
1-tert-Butyl 4-methyl N-(benzyloxy)methoxy-D-aspartate (3ad): The reaction was carried out using 1a 
(34.4 mg, 200 µmol, 1.0 equiv) and 2d (36.7 mg, 220 µmol, 1.1 equiv) in the 
presence of catalyst A (7.9 mg, 20 μmol, 10 mol%) and benzoic acid (48.8 mg, 
400 μmol, 1.0 equiv) and 4 Å MS (200.0 mg) for 24 h. The crude product was 
purified by silica-gel column chromatography (eluent: hexane/EtOAc, 3:1) 
afforded 3ad as colorless oil (40.0 mg, 122 μmol, 60%, 87% ee). 
 [α]D
25 4.4 (c 1.06, CHCl3); IR (neat) ν�: 1731 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.31 (m, 5H), 6.43 (d, 
J = 6.4 Hz, 1H), 4.86 (s, 2H), 4.65 (s, 2H), 3.98 (dt, J = 10.0, 6.4 Hz, 1H), 3.69 (s, 3H), 2.77 (dd, J = 16.4, 
6.4 Hz, 1H), 2.67 (dd, J = 16.4, 6.4 Hz, 1H), 1.48 (s, 9H) ppm; 13C NMR (100 MHz, CDCl3) δ: 171.2, 
170.6, 137.7, 128.4, 127.79, 127.67, 82.1, 69.9, 60.8, 51.8, 34.4, 27.9 ppm; HRMS (ESI) m/z calcd. for 
C17H25NO6, [M+Na]+: 362.1574, found: 362.1588. The enantiomeric excess was estimated by chiral HPLC 
analysis (DAICEL CHIRALPAK IB, eluent: hexane/2-propanol = 98/2, flow rate: 1.0 mL/min. detector: 
UV at 220 nm), tR = 16.1 min (major), 17.4 min (minor). 
 
1-tert-Butyl 4-methyl N-(2-trimethylsilylethoxy)methoxy-D-aspartate (3ae): The reaction was carried 
out using 1a (34.4 mg, 200 µmol, 1.0 equiv) and 2e (33.6 mg, 220 µmol, 
1.1 equiv) in the presence of catalyst A (7.9 mg, 20 μmol, 10 mol%),  
benzoic acid (48.8 mg, 400 μmol, 1.0 equiv) and 4 Å MS (200.0 mg) 
for 24 h. The crude product was purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 3:1) afforded 3ae as colorless oil (48.9 mg, 142 μmol, 70%). Since 
3ae was not detectable on HPLC, N-benzoylation was conducted to estimate the ee of 3ae. 
 [α]D
25 +4.3 (c 1.00, CHCl3); IR (neat) ν�: 1738 cm-1; 1H NMR (400 MHz, CDCl3) δ: 6.36 (d, J = 6.4 Hz, 
1H), 4.75 (s, 2H), 3.94 (dt, J = 12.8 Hz, 6.4 Hz), 3.68 (s, 3H), 3.62 (t, J = 8.4 Hz, 2H), 1.45 (s, 9H), 0.94 (t, 
J = 8.4 Hz, 2H) ppm; 13C NMR (125 MHz, CDCl3) δ: 171.2, 170.6, 97.7, 82.0, 65.7, 60.8, 51.8, 34.4, 27.9, 























1-tert-Butyl 4-methyl N-benzoyl-N-(2-trimethylsilylethoxy)methoxy-D-aspartate (3ae’): To a solution 
of 3ae (34.9 mg, 100 μmol, 1.0 equiv) in EtOAc (1mL) were added 
BzCl (21.1 mg, 150 µmol, 1.5 equiv) and sat. NaHCO3 aq. (1 mL) at 0 
ºC. The mixture was allowed to warm to room temperature and stirred 
for 3 h. Added brine (2 mL) and extracted with EtOAc (5 mL, 2 times). 
The crude product was purified by silica-gel column chromatography (eluent: hexane/EtOAc, 5:1) afforded 
3ae’ as colorless oil (38.8 mg, 85 μmol, 85%). 
 [α]D
25 0.71 (c 5.84, CHCl3); IR (neat) ν�: 1736, 1648 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.67 (d, J = 7.0 
Hz, 2H), 7.46 (t, J = 7.0 Hz, 1H), 7.41 (t, J = 7.0 Hz, 2H) 5.06 (br, 1H), 4.85 (br, 2H), 3.73 (s, 3H), 3.49 
(s, 2H), 3.21 (dd, J = 17.0, 7.0 Hz, 1H), 2.97 (dd, J = 17.0, 7.0 Hz, 1H), 1.48 (s, 9H), 0.85 (t, J = 8.0 Hz, 
2H), 0.018 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 198.7, 171.3, 167.6, 134.2, 130.9, 128.3, 128.2, 
99.6, 82.9, 67.7, 61.1, 52.0, 34.0, 27.9, 17.9 ppm; HRMS (ESI) m/z calcd. for C22H35NO7Si, [M+H]+: 
453.2111, found: 453.2183. The enantiomeric excess was estimated by chiral HPLC analysis (DAICEL 
CHIRALPAK IB, eluent: hexane/2-propanol = 1, flow rate: 1.0 mL/min. detector: UV at 254 nm), tR = 18.9 
min (major), 23.7 min (minor). 
 
1-Benzyl 4-methyl N-(2-trimethylsilylethoxy)methoxy-L-aspartate (3be): The reaction was carried out 
using 1b (82.5 mg, 400 µmol, 1.0 equiv) and 2e (67.3 mg, 440 µmol, 
1.1 equiv) in the presence of catalyst ent-A (15.9 mg, 40 μmol, 10 
mol%), benzoic acid (48.8 mg, 400 μmol, 1.0 equiv) and 4 Å MS (200.0 
mg) for 24 h. The crude product was purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 3:1) afforded 3be as colorless oil (268.4 mg, 284 μmol, 70%, 86% 
ee). 
 [α]D
26 +4.7 (c 1.00, CHCl3); IR (neat) ν�: 1739 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.35 (m, 5H), 6.42 (d 
J = 7.0 Hz, 1H), 5.21 (s, 2H), 4.76 (s, 2H), 4.12 (dt, J = 7.0, 6.0Hz, 1H), 3.65 (s, 3H), 3.62 (dt, J = 8.5, 1.0 
Hz, 1H), 2.85 (dd, J = 16.0, 6.0Hz, 1H) 2.74 (dd, J = 16.0, 6.0 Hz, 1H), 0.94 (dt, J = 8.5, 1.2 Hz, 2H), 0.01 
(s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 171.4, 170.9, 135.2, 128.5, 128.3, 128.2, 97.8, 67.1, 65.8, 
60.2, 51.9, 34.1, 18.0 ppm; HRMS (ESI) m/z calcd. for C18H29NO6Si, [M+Na]+: 406.1656, found: 406.1643.  
The enantiomeric excess was estimated by chiral HPLC analysis (DAICEL CHIRALPAK IB, eluent: 
hexane/2-propanol = 99/1, flow rate: 1.0 mL/min. detector: UV at 254 nm), tR = 16.4 min (major), 18.2 min 
(minor). 
 
1-tert-Butyl 4-methyl 9H-fluoren-9-ylmethoxycarbonyl-D-aspartate (S3aa): 3aa (25.3 mg 100 µmol, 
1.0 equiv) was dissolved in MeOH (30 mL) and added to 10% Pd/C (80 mg) under 
an atmosphere of argon. The reaction was carefully flushed with hydrogen gas and 
stirred at room temperature for 5 h. The atmosphere was replaced with argon before 
filtration through a pad of Celite®. The filtrate was concentrated under reduced pressure and the residue 
was dissolved in CH2Cl2 (1.0 mL). To the solution were added iPr2NEt (64.6 mg, 500 µmol, 5.0 equiv) and 
FmocCl (25.8 mg, 120 µmol, 1.2 equiv). The resulting mixture was stirred at ambient temperature for 17 






















hexane/EtOAc, 1:1) to afford S3aa as colorless oil (26.0 mg, 61 μmol, 61%). 
 [α]D
23 -7.1 (c 0.73, CHCl3); IR (neat) ν�: 3368, 1721 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.75 (d, J = 7.5 
Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.40 (t, J = 7.5 Hz, 2H), 5.80 (d, J = 8.5 Hz, 1H), 4.54 (dt, J = 8.5, 4.5 
Hz, 1H), 4.38 (dt, J = 17.0, 7.0 Hz, 2H), 4.23 (t, J = 7.0 Hz, 1H), 3.71 (s, 3H), 3.00 (dd, J = 17.0, 4.0 Hz, 
1H), 2.84 (dd, J = 17.0, 4.0 Hz, 1H), 1.48 (s, 9H) ppm; 13C NMR (125 MHz, CDCl3) δ: 171.3, 169.6, 156.0, 
143.9, 143.8, 141.3, 127.8, 127.1, 125.2, 120.0, 82.7, 67.2, 52.0, 51.0, 47.2, 36.8, 27.9 ppm; HRMS (ESI) 
m/z calcd. for 448.1731, [M+Na]+ found: 448.1757. The enantiomeric excess was estimated by chiral HPLC 
analysis (DAICEL CHIRALPAK IA, eluent: hexane/2-propanol = 96/4, flow rate: 1.0 mL/min. detector: 
UV at 254 nm), tR = 20.3 min (major), 26.6 min (minor). 
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1-Benzyl 4-methyl N-hydroxy-L-aspartate (4b): To a solution of 3be (192.7 mg, 500 μmol, 1.0 equiv) in 
CH2Cl2 (5 mL) was added TFA (172.5 mg, 1.5 mmol, 3.0 equiv) at room temperature and stirred for 1 h. 
H2O (5 mL) was added and further stirred at ambient temperature for 1 h, and the mixture was dried over 
Na2SO4. The solids were filtered off and the solvent was removed under reduced presssure. The residue 
was then purified by silica-gel column chromatography (eluent: hexane/EtOAc, 1:2) to afford 4b as 
colorless oil (53.1 mg, 210 μmol, 42%). Since 4b was gradually degraded on standing, 4b was used for 
KAHA ligation soon after purification. 
1H NMR (500 MHz, CDCl3) δ: 7.32 (m, 5H), 5.22 (s, 2H), 4.06 (dt, J = 8.0, 5.0 Hz, 1H), 3.66 (s, 3H), 2.87 
(dd, J = 16.0, 5.0 Hz, 1H), 2.80 (dd, J = 16.0, 5.0 Hz, 1H) ppm. 
 
1-Benzyl 4-methyl (3-phenylpropanoyl)-L-aspartate (6b): A mixture of 4b (23.3 mg, 92 µmol, 1.0 equiv) 
and 2-oxo-4-phenylbutanoic acid (5) (16.3 mg, 92 µmol, 1.0 equiv) in 
DMSO/H2O (9:1, 200 µL) was stirred at 40 ºC for 24 h. The crude mixture was 
extracted with EtOAc (2 mL, 3 times) and then purified by silica-gel column 
chromatography (eluent: hexane/EtOAc, 1:2) to afford to 6b as yellow oil (26.1 
mg, 70 µmol, 60%, 82% ee). 
 [α]D










(m, 6H), 7.27-7.24 (m, 1H), 7.19-7.17 (m, 3H), 6.42 (d, J = 8.0 Hz, 1H), 5.17 (dd, J = 28.0, 12.5 Hz, 2H), 
4.88 (dt, J = 8.0, 4.0 Hz, 1H), 3.00 (dd, J = 17.5, 4.0 Hz, 1H), 2.95 (t, J = 8.0 Hz, 2H), 2.75 (dd, J = 17.5, 
4.0 Hz, 1H), 2.59 (ddd, J = 18.0, 15.0, 8.0 Hz, 1H), 2.49 (ddd, J = 18.0 Hz, 15.0, 8.0 Hz) ppm; 13C NMR 
(125 MHz, CDCl3) δ: 171.8, 171.4, 170.5, 140.5, 135.1, 128.55, 128.45, 128.26, 126.1, 67.5, 51.9, 48.3, 
38.0, 36.0, 31.4 ppm; HRMS (ESI) m/z calcd. For C21H23NO5, [M+H]+: 370.1649, found: 370.1676. The 
enantiomeric excess was estimated by chiral HPLC analysis (DAICEL CHIRALPAK IB, eluent: hexane/2-
propanol = 99/1, flow rate: 1 mL/min. detector: UV at 254 nm), tR = 18.2 min (minor), 16.4 min (major). 
 
1-Benzyl 4-methyl 9H-fluoren-9-ylmethoxycarbonyl-L-leucyl-L-aspartate (8b): A mixture of 4b (60.1 
mg, 156 µmol, 1.0 equiv) and (S)-3-(9H-fluoren-9-
ylmethoxycarbonyl)amino)-5-methyl-2-oxohexanoic acid (7) (57.1 mg, 150 
µmol, 1.0 equiv) in DMSO/H2O (9:1, 15 mL) was stirred at 40 ºC for 15 h. 
The crude mixture was extracted with EtOAc (2 mL, 3 times) and then 
purified by silica-gel column chromatography (eluent: hexane/EtOAc, 1:2) to 
afford to 8b as yellow oil (41.2 mg, 72 µmol, 50%, 93:7 dr). 
 [α]D
23 -3.20 (c 1.20, CHCl3); IR (neat) ν�: 3314, 1738, 1661 cm-1; 1H NMR (500 MHz, CDCl3) δ: 7.75 (d, 
J = 7.0 Hz, 2H), 7.57 (d, J = 5.5 Hz, 2H), 7.39-7.29 (m, 9H), 6.95 (d, J = 8.0 Hz, 1H), 5.34 (d, J = 8.0 Hz, 
1H), 5.15 (dd, J = 21.0, 12.0 Hz, 2H), 4.91 (t, J = 4.0 Hz, 1H), 4.36 (m, 2H) 4.21 (m, 2H), 3.58 (s, 3H), 
3.05 (dd, J = 17.0, 3.5 Hz, 1H), 2.81 (dd, J = 17.0, 3.5 Hz, 1H), 1.63 (m, 2H), 1.50 (m, 1H), 0.89 (s, 6H) 
ppm; 13C NMR (125 MHz, CDCl3) δ: 172.2, 171.5, 170.3, 156.1, 143.9, 143.8, 141.3, 135.1, 128.69, 128.60, 
128.4, 127.8, 127.1, 125.1, 120.0, 67.7, 67.1, 53.4, 52.1, 48.5, 41.9, 36.0, 24.6, 22.9, 22.0 ppm; HRMS 













[1] N. Hayama, T. Azuma, Y. Kobayashi, Y. Takemoto, Chem. Pharm. Bull., 2016, 64, 704. 
[2] S. E. Denmark, A. Thorarensen, D. S. Middleton, J. Am. Chem. Soc., 1996, 118, 8266. 
[3] D. Hadjipavlou-Litina, G. E. Magoulas, M. Krokidis, D. Papaioannou, Eur. J. Med. Chem., 2010, 45, 
298. 
[4] J. P. D. van Veldhoven, C. C. Blad, A. C. Klopman, D. R. Wolfram, M. J. Abdelkadir, J. R. Lane, J. 
Brussee, A. P. IJzerman, Bioorg. Med. Chem. Lett., 2011, 21, 2736. 
[5] Ö. D. Ekici, Z. Z. Li, A. J. Campbell, K. E. James, J. L. Asgian, J. Mikolajczyk, G. S. Salvesen, R. 
Ganesan, S. Jelakovic, M. G. Grütter, J. C. Powers, J. Med. Chem., 2006, 49, 5728. 
[6] A. Odriozola, M. Oiarbide, C. Palomo, Chem. Eur. J., 2017, 23, 12758. 













































































































































































































































































































































































































































































(G) HPLC Traces 
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